THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients(1), and in particular Article 7 thereof,
Whereas:
(1) On 29 September 2006 the company Neptune Technologies & Bioressources Inc. made a request to the competent authorities of Finland to place a lipid extract from Antarctic Krill Euphausia superba on the market as a novel food ingredient.
(2) On 29 January 2007 the competent food assessment body of Finland issued its initial assessment report. In that report it came to the conclusion that the use of the lipid extract from Antarctic Krill Euphausia superba as a food ingredient was acceptable.
(3) The Commission forwarded the initial assessment report to all Member States on 19 February 2007.
(4) Within the 60-day period laid down in Article 6(4) of Regulation (EC) No 258/97 reasoned objections to the marketing of the product were raised in accordance with that provision.
(5) Therefore the European Food Safety Authority (EFSA) was consulted on 31 January 2008.
(6) In the Scientific Opinion of the Panel on dietetic products nutrition and allergies on a request from the European Commission on the safety of lipid extract from Euphausia superba as food ingredient, the panel came to the conclusion that the lipid extract from Antarctic Krill Euphausia superba was safe under the proposed conditions of use.
(7) On the basis of the initial assessment report, it is established that the lipid extract from Antarctic Krill Euphausia superba complies with the criteria laid down in Article 3(1) of the Regulation.
(8) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,
HAS ADOPTED THIS DECISION:
Lipid extract from Antarctic Krill Euphausia superba as specified in Annex I, may be placed on the market in the Community as a novel food ingredient for the uses and at the maximum levels as listed in Annex II.
The designation ‘lipid extract from the crustacean Antarctic Krill Euphausia superba’ shall be displayed on the labelling of the product as such or in the list of ingredients of foodstuffs containing it.
This Decision is addressed to Neptune Technologies & Bioressources Inc., 225 Promenade du Centropolis, Suite 200, Laval, Quebec H7T 0B3, Canada.
Done at Brussels, 12 October 2009.
For the Commission
Androulla Vassiliou
Member of the Commission
To produce lipid extract from Antarctic Krill Euphausia superba deep-frozen Antarctic krill is crushed and subjected to an extraction with acetone. Proteins and krill material are removed from the lipid extract by filtration. The acetone and residual water are removed by evaporation.
| Test | Specification |
|---|---|
| Saponification value | Not more than 185 mg KOH/g |
| Peroxide value (PV) | Not more than 0,2 meq O2/kg oil |
| Moisture and volatiles | Not more than 0,9 % |
| Phospholipids | Not more than 50 % |
| Trans-fatty acids | Not more than 1 % |
| EPA (eicosapentaenoic acid) | Not less than 15 % |
| DHA (docosahexaenoic acid) | Not less than 7 % |
| Use group | Maximum content of combined DHA and EPA |
|---|---|
| Dairy products except milk-based drinks | 200 mg/100 g or for cheese products 600 mg/100 g |
| Dairy analogues except drinks | 200 mg/100 g or for analogues to cheese products 600 mg/100 g |
| Spreadable fat and dressings | 600 mg/100 g |
| Breakfast cereals | 500 mg/100 g |
| Food supplements | 200 mg per daily dose as recommended by the manufacturer |
| Dietary foods for special medical purposes | In accordance with the particular nutritional requirements of the persons for whom the products are intended |
| Foods intended for use in energy restricted diets for weight reduction | 200 mg/meal replacement |